• Sign in to follow this  

    Acadia Pharma (ACAD) Advisory Panel of Nuplazid for Parkinson's disease psychosis

       (1 review)

    Biotech Forecast
    Clinical and Regulatory
    Event Type: Advisory Panel
    Timing: 03/29/2016
    Designation(s): Breakthrough Therapy, Priority Review

    This event is set for a specific date and makes planning easier. However, specific dates may change.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Neurology
    Indication: Parkinson's Psychosis
    Lead Indication?: Yes
    Treatment Name: NUPLAZID™ (pimavanserin)

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Acadia Pharmaceuticals
    Stock Symbol: ACAD
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=2133696
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement



    SAN DIEGO--(BUSINESS WIRE)--Jan. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in ACADIA’s New Drug Application (NDA) for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. The Advisory Committee Meeting is scheduled for March 29.


    Edited by Biotech Forecast

      Report Event
    Sign in to follow this  

    User Feedback